

**Ivermectin Liquid Formulation**

Version 8.2      Revision Date: 04/09/2022      SDS Number: 1204379-00015      Date of last issue: 03/26/2022  
Date of first issue: 01/09/2017

---

**SECTION 1. IDENTIFICATION**

Product name : Ivermectin Liquid Formulation

**Manufacturer or supplier's details**

Company name of supplier : Merck & Co., Inc  
Address : 126 E. Lincoln Avenue  
Rahway, New Jersey U.S.A. 07065  
Telephone : 908-740-4000  
Emergency telephone : 1-908-423-6000  
E-mail address : EHSDATASTEWARD@merck.com

**Recommended use of the chemical and restrictions on use**



Recommended use : Veterinary product  
Restrictions on use : Not applicable

---

**SECTION 2. HAZARDS IDENTIFICATION****GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)**

Skin irritation : Category 2  
Eye irritation : Category 2A  
Reproductive toxicity : Category 1B  
Specific target organ toxicity : Category 1 (Central nervous system)  
- single exposure (Oral)  
Specific target organ toxicity : Category 3  
- single exposure  
Specific target organ toxicity : Category 1 (Central nervous system)  
- repeated exposure (Oral)

**GHS label elements**

Hazard pictograms :  

Signal Word : Danger

Hazard Statements : H315 Causes skin irritation.  
H319 Causes serious eye irritation.  
H335 May cause respiratory irritation.  
H360D May damage the unborn child.  
H370 Causes damage to organs (Central nervous system) if swallowed.  
H372 Causes damage to organs (Central nervous system) through prolonged or repeated exposure if swallowed.

---



## Ivermectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03/26/2022
8.2	04/09/2022	1204379-00015	Date of first issue: 01/09/2017

---

- |   |   |  |
|---|---|--|
| In case of skin contact                                     | : | Get medical attention.<br>In case of contact, immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.<br>Get medical attention.<br>Wash clothing before reuse.<br>Thoroughly clean shoes before reuse. |
| In case of eye contact                                      | : | In case of contact, immediately flush eyes with plenty of water for at least 15 minutes.<br>If easy to do, remove contact lens, if worn.<br>Get medical attention.   |
| If swallowed  | : | If swallowed, DO NOT induce vomiting.<br>Get medical attention.<br>Rinse mouth thoroughly with water.<br>Never give anything by mouth to an unconscious person.  |
| Most important symptoms and effects, both acute and delayed | : | Causes skin irritation.<br>Causes serious eye irritation.<br>May cause respiratory irritation.<br>May damage the unborn child.<br>Causes damage to organs if swallowed.<br>Causes damage to organs through prolonged or repeated exposure if swallowed.            |
| Protection of first-aiders                                  | : | First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).  |
| Notes to physician  | : | Treat symptomatically and supportively.  |
- 

### SECTION 5. FIRE-FIGHTING MEASURES

- |  |   |   |
|--|---|---|
| Suitable extinguishing media                   | : | Water spray<br>Alcohol-resistant foam<br>Carbon dioxide (CO <sub>2</sub> )<br>Dry chemical  |
| Unsuitable extinguishing media                 | : | None known.   |
| Specific hazards during fire fighting          | : | Exposure to combustion products may be a hazard to health.  |
| Hazardous combustion products                  | : | Carbon oxides<br>Nitrogen oxides (NO <sub>x</sub> )   |
| Specific extinguishing methods                 | : | Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.<br>Use water spray to cool unopened containers.<br>Remove undamaged containers from fire area if it is safe to do so.<br>Evacuate area. |
| Special protective equipment for fire-fighters | : | In the event of fire, wear self-contained breathing apparatus.<br>Use personal protective equipment.  |
- 

### SECTION 6. ACCIDENTAL RELEASE MEASURES

- |   |   |  |
|---|---|--|
| Personal precautions, protective equipment and emergency procedures | : | Use personal protective equipment.<br>Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8). |
|---|---|--|

## Ivermectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03/26/2022
8.2	04/09/2022	1204379-00015	Date of first issue: 01/09/2017

---

- Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Prevent spreading over a wide area (e.g., by containment or oil barriers).  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.
- Methods and materials for containment and cleaning up : Soak up with inert absorbent material.  
For large spills, provide diking or other appropriate containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate container.  
Clean up remaining materials from spill with suitable absorbent.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

---

### SECTION 7. HANDLING AND STORAGE

- Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
- Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.
- Advice on safe handling : Do not get on skin or clothing.  
Do not breathe mist or vapors.  
Do not swallow.  
Do not get in eyes.  
Wash skin thoroughly after handling.  
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
Keep container tightly closed.  
Already sensitized individuals, and those susceptible to asthma, allergies, chronic or recurrent respiratory disease, should consult their physician regarding working with respiratory irritants or sensitizers.  
Do not eat, drink or smoke when using this product.  
Take care to prevent spills, waste and minimize release to the environment.
- Conditions for safe storage : Keep in properly labeled containers.  
Store locked up.  
Keep tightly closed.  
Keep in a cool, well-ventilated place.  
Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:  
Strong oxidizing agents  
Self-reactive substances and mixtures  
Organic peroxides  
Explosives

## Ivermectin Liquid Formulation

Version 8.2      Revision Date: 04/09/2022      SDS Number: 1204379-00015      Date of last issue: 03/26/2022  
 Date of first issue: 01/09/2017

## Gases

## SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

## Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
N-Methyl-2-pyrrolidone	872-50-4	TWA	15 ppm 60 mg/m <sup>3</sup>	US WEEL
		STEL	30 ppm 120 mg/m <sup>3</sup>	US WEEL
Ivermectin	70288-86-7	TWA	0.3 mg/m <sup>3</sup> (OEB 3)	Internal
Further information: Skin				
		Wipe limit	300 mg/100 cm <sup>2</sup>	Internal

## Biological occupational exposure limits

Components	CAS-No.	Control parameters	Biological specimen	Sampling time	Permissible concentration	Basis
N-Methyl-2-pyrrolidone	872-50-4	5-Hydroxy-N-methyl-2-pyrrolidone	Urine	End of shift (As soon as possible after exposure ceases)	100 mg/l	ACGIH BEI

**Engineering measures** : Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).  
 All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.  
 Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).  
 Minimize open handling.

**Personal protective equipment**

**Respiratory protection** : General and local exhaust ventilation is recommended to maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided by air purifying respirators against exposure to any hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other circumstance where air purifying respirators may not provide

## Ivermectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03/26/2022
8.2	04/09/2022	1204379-00015	Date of first issue: 01/09/2017

---

Hand protection	: adequate protection.
Material	: Chemical-resistant gloves
Remarks	: Consider double gloving.
Eye protection	: Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Skin and body protection	: Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.
Hygiene measures	: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

---

### SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	: liquid
Color	: light yellow
Odor	: characteristic
Odor Threshold	: No data available
pH	: No data available
Melting point/freezing point	: No data available
Initial boiling point and boiling range	: No data available
Flash point	: > 212 °F / > 100 °C
Evaporation rate	: No data available
Flammability (solid, gas)	: Not applicable
Flammability (liquids)	: No data available

**Ivermectin Liquid Formulation**

Version      Revision Date:      SDS Number:      Date of last issue: 03/26/2022  
8.2          04/09/2022          1204379-00015      Date of first issue: 01/09/2017

---

Upper explosion limit / Upper flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available

Vapor pressure : No data available

Relative vapor density : No data available

Relative density : No data available

Density : 0.90 - 0.92 g/cm<sup>3</sup>

Solubility(ies)  
Water solubility : insoluble

Partition coefficient: n-octanol/water : Not applicable

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity  
Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle size : Not applicable

---

**SECTION 10. STABILITY AND REACTIVITY**

Reactivity : Not classified as a reactivity hazard.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reactions : Can react with strong oxidizing agents.

Conditions to avoid : None known.

Incompatible materials : Oxidizing agents

Hazardous decomposition products : No hazardous decomposition products are known.

---

**SECTION 11. TOXICOLOGICAL INFORMATION****Information on likely routes of exposure**

Inhalation  
Skin contact  
Ingestion  
Eye contact

**Ivermectin Liquid Formulation**

Version 8.2      Revision Date: 04/09/2022      SDS Number: 1204379-00015      Date of last issue: 03/26/2022  
Date of first issue: 01/09/2017

---

**Acute toxicity**

Not classified based on available information.

**Product:**

Acute oral toxicity : Acute toxicity estimate: 4,462 mg/kg  
Method: Calculation method

Acute dermal toxicity : Acute toxicity estimate: > 5,000 mg/kg  
Method: Calculation method

**Components:****N-Methyl-2-pyrrolidone:**

Acute oral toxicity : LD50 (Rat): 4,150 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5.1 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist  
Method: OECD Test Guideline 403

Acute dermal toxicity : LD50 (Rat): > 5,000 mg/kg

**Ivermectin:**

Acute oral toxicity : LD50 (Rat): 50 mg/kg  
LD50 (Mouse): 25 mg/kg  
LD50 (Monkey): > 24 mg/kg  
Target Organs: Central nervous system  
Symptoms: Vomiting, Dilatation of the pupil  
Remarks: No mortality observed at this dose.

Acute inhalation toxicity : LC50 (Rat): 5.11 mg/l  
Exposure time: 1 h  
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): 406 mg/kg  
LD50 (Rat): > 660 mg/kg

**Skin corrosion/irritation**

Causes skin irritation.

**Components:****N-Methyl-2-pyrrolidone:**

Result : Skin irritation

**Ivermectin:**

Species : Rabbit  
Result : No skin irritation



**Ivermectin Liquid Formulation**

Version 8.2      Revision Date: 04/09/2022      SDS Number: 1204379-00015      Date of last issue: 03/26/2022  
Date of first issue: 01/09/2017

---

**Serious eye damage/eye irritation**

Causes serious eye irritation.

**Components:****N-Methyl-2-pyrrolidone:**

Species : Rabbit  
Result : Irritation to eyes, reversing within 21 days

**Ivermectin:**

Species : Rabbit  
Result : Mild eye irritation

**Respiratory or skin sensitization****Skin sensitization**

Not classified based on available information.

**Respiratory sensitization**

Not classified based on available information.

**Components:****N-Methyl-2-pyrrolidone:**

Test Type : Local lymph node assay (LLNA)  
Routes of exposure : Skin contact  
Species : Mouse  
Method : OECD Test Guideline 429  
Result : negative  
Remarks : Based on data from similar materials

**Ivermectin:**

Routes of exposure : Dermal  
Species : Humans  
Result : Does not cause skin sensitization.

**Germ cell mutagenicity**

Not classified based on available information.

**Components:****N-Methyl-2-pyrrolidone:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Method: OECD Test Guideline 471  
Result: negative

Test Type: In vitro mammalian cell gene mutation test  
Method: OECD Test Guideline 476  
Result: negative

Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)  
Result: negative

## Ivermectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03/26/2022
8.2	04/09/2022	1204379-00015	Date of first issue: 01/09/2017

---

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)  
 Species: Mouse  
 Application Route: Ingestion  
 Method: OECD Test Guideline 474  
 Result: negative

Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)  
 Species: Hamster  
 Application Route: Ingestion  
 Method: OECD Test Guideline 475  
 Result: negative

### Ivermectin:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
 Result: negative

Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)  
 Test system: human diploid fibroblasts  
 Result: negative

Test Type: Mouse Lymphoma  
 Result: negative

### Carcinogenicity

Not classified based on available information.

### Components:

#### **N-Methyl-2-pyrrolidone:**

Species : Rat  
 Application Route : Ingestion  
 Exposure time : 2 Years  
 Result : negative

Species : Rat  
 Application Route : inhalation (vapor)  
 Exposure time : 2 Years  
 Result : negative

#### **Ivermectin:**

Species : Rat  
 Application Route : Oral  
 NOAEL : 1.5 mg/kg body weight  
 Result : negative  
 Remarks : Based on data from similar materials

Species : Mouse  
 Application Route : Oral  
 NOAEL : 2.0 mg/kg body weight  
 Result : negative

## Ivermectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03/26/2022
8.2	04/09/2022	1204379-00015	Date of first issue: 01/09/2017

---

Remarks : Based on data from similar materials

**IARC** No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

**OSHA** No component of this product present at levels greater than or equal to 0.1% is on OSHA's list of regulated carcinogens.

**NTP** No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

**Reproductive toxicity**

May damage the unborn child.

**Components:****N-Methyl-2-pyrrolidone:**

Effects on fertility : Test Type: Two-generation reproduction toxicity study  
Species: Rat  
Application Route: Ingestion  
Method: OECD Test Guideline 416  
Result: negative

Effects on fetal development : Test Type: Embryo-fetal development  
Species: Rat  
Application Route: Ingestion  
Method: OECD Test Guideline 414  
Result: positive

Test Type: Fertility/early embryonic development  
Species: Rat  
Application Route: inhalation (vapor)  
Result: positive

Test Type: Embryo-fetal development  
Species: Rabbit  
Application Route: Ingestion  
Result: positive

Reproductive toxicity - Assessment : Clear evidence of adverse effects on development, based on animal experiments.

**Ivermectin:**

Effects on fertility : Test Type: Fertility  
Species: Rat  
Application Route: Oral  
Fertility: NOAEL: 0.6 mg/kg body weight  
Result: Animal testing did not show any effects on fertility.

Effects on fetal development : Test Type: Development  
Species: Mouse  
Application Route: Oral  
Developmental Toxicity: NOAEL: 0.2 mg/kg body weight  
Result: Teratogenic effects., Embryotoxic effects and adverse

## Ivermectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03/26/2022
8.2	04/09/2022	1204379-00015	Date of first issue: 01/09/2017

---

effects on the offspring were detected only at high maternally toxic doses

Test Type: Development  
 Species: Rat  
 Application Route: Oral  
 Developmental Toxicity: LOAEL: 0.4 mg/kg body weight  
 Result: Embryotoxic effects and adverse effects on the offspring were detected.  
 Remarks: The mechanism or mode of action may not be relevant in humans.

Test Type: Development  
 Species: Rabbit  
 Application Route: Oral  
 Result: Teratogenic effects., Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses

### STOT-single exposure

May cause respiratory irritation.  
 Causes damage to organs (Central nervous system) if swallowed.

#### Components:

#### **N-Methyl-2-pyrrolidone:**

Assessment : May cause respiratory irritation.

#### **Ivermectin:**

Target Organs : Central nervous system  
 Assessment : Causes damage to organs.

### STOT-repeated exposure

Causes damage to organs (Central nervous system) through prolonged or repeated exposure if swallowed.

#### Components:

#### **Ivermectin:**

Target Organs : Central nervous system  
 Assessment : Causes damage to organs through prolonged or repeated exposure.

### Repeated dose toxicity

#### Components:

#### **N-Methyl-2-pyrrolidone:**

Species : Rat, male  
 NOAEL : 169 mg/kg  
 LOAEL : 433 mg/kg  
 Application Route : Ingestion  
 Exposure time : 90 Days

## Ivermectin Liquid Formulation

Version 8.2      Revision Date: 04/09/2022      SDS Number: 1204379-00015      Date of last issue: 03/26/2022  
 Date of first issue: 01/09/2017

Method : OECD Test Guideline 408

Species : Rat  
 NOAEL : 0.5 mg/l  
 LOAEL : 1 mg/l  
 Application Route : inhalation (dust/mist/fume)  
 Exposure time : 96 Days  
 Method : OECD Test Guideline 413

Species : Rabbit  
 NOAEL : 826 mg/kg  
 LOAEL : 1,653 mg/kg  
 Application Route : Skin contact  
 Exposure time : 20 Days

### **Ivermectin:**

Species : Dog  
 NOAEL : 0.5 mg/kg  
 LOAEL : 1 mg/kg  
 Application Route : Oral  
 Exposure time : 14 Weeks  
 Target Organs : Central nervous system  
 Symptoms : Dilatation of the pupil, Tremors, Lack of coordination, anorexia

Species : Monkey  
 NOAEL : 1.2 mg/kg  
 Application Route : Oral  
 Exposure time : 2 Weeks  
 Remarks : No significant adverse effects were reported

Species : Rat  
 NOAEL : 0.4 mg/kg  
 LOAEL : 0.8 mg/kg  
 Application Route : Oral  
 Exposure time : 3 Months  
 Target Organs : spleen, Bone marrow, Kidney

### **Aspiration toxicity**

Not classified based on available information.

### **Experience with human exposure**

#### **Components:**

#### **N-Methyl-2-pyrrolidone:**

Skin contact : Symptoms: Skin irritation

#### **Ivermectin:**

Skin contact : Remarks: Can be absorbed through skin.  
 Eye contact : Remarks: May irritate eyes.  
 Ingestion : Symptoms: Drowsiness, Dilatation of the pupil, Tremors, Vomiting, anorexia, Lack of coordination

**Ivermectin Liquid Formulation**

Version 8.2      Revision Date: 04/09/2022      SDS Number: 1204379-00015      Date of last issue: 03/26/2022  
Date of first issue: 01/09/2017

---

**SECTION 12. ECOLOGICAL INFORMATION****Ecotoxicity****Components:****N-Methyl-2-pyrrolidone:**

- Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): > 500 mg/l  
Exposure time: 96 h
- Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 1,000 mg/l  
Exposure time: 24 h  
Method: DIN 38412
- Toxicity to algae/aquatic plants : ErC50 (Desmodesmus subspicatus (green algae)): 600.5 mg/l  
Exposure time: 72 h
- EC10 (Desmodesmus subspicatus (green algae)): 92.6 mg/l  
Exposure time: 72 h
- Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 12.5 mg/l  
Exposure time: 21 d  
Method: OECD Test Guideline 211
- Toxicity to microorganisms : EC50: > 600 mg/l  
Exposure time: 30 min  
Method: ISO 8192

**Ivermectin:**

- Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): 0.003 mg/l  
Exposure time: 96 h
- LC50 (Lepomis macrochirus (Bluegill sunfish)): 0.0048 mg/l  
Exposure time: 96 h
- Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 0.000025 mg/l  
Exposure time: 48 h
- Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 9.1 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201
- NOEC (Pseudokirchneriella subcapitata (green algae)): 9.1 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201

**Persistence and degradability****Components:****N-Methyl-2-pyrrolidone:**

**Ivermectin Liquid Formulation**

Version 8.2      Revision Date: 04/09/2022      SDS Number: 1204379-00015      Date of last issue: 03/26/2022  
Date of first issue: 01/09/2017

---

Biodegradability : Result: Readily biodegradable.  
Biodegradation: 73 %  
Exposure time: 28 d  
Method: OECD Test Guideline 301C

**Ivermectin:**

Biodegradability : Result: Not readily biodegradable.  
Biodegradation: 50 %  
Exposure time: 240 d

**Bioaccumulative potential****Components:****N-Methyl-2-pyrrolidone:**

Partition coefficient: n-octanol/water : log Pow: -0.46  
Method: OECD Test Guideline 107

**Ivermectin:**

Bioaccumulation : Bioconcentration factor (BCF): 74

Partition coefficient: n-octanol/water : log Pow: 3.22

**Mobility in soil**

No data available

**Other adverse effects**

No data available

---

**SECTION 13. DISPOSAL CONSIDERATIONS****Disposal methods**

Waste from residues : Dispose of in accordance with local regulations.  
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

---

**SECTION 14. TRANSPORT INFORMATION****International Regulations****UNRTDG**

UN number : UN 3082  
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (Ivermectin)  
Class : 9  
Packing group : III  
Labels : 9

**IATA-DGR**

UN/ID No. : UN 3082

---

## Ivermectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03/26/2022
8.2	04/09/2022	1204379-00015	Date of first issue: 01/09/2017

---

Proper shipping name : Environmentally hazardous substance, liquid, n.o.s. (Ivermectin)

Class : 9

Packing group : III

Labels : Miscellaneous

Packing instruction (cargo aircraft) : 964

Packing instruction (passenger aircraft) : 964

Environmentally hazardous : yes

**IMDG-Code**

UN number : UN 3082

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (Ivermectin)

Class : 9

Packing group : III

Labels : 9

EmS Code : F-A, S-F

Marine pollutant : yes

**Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code**

Not applicable for product as supplied.

**Domestic regulation****49 CFR**

UN/ID/NA number : UN 3082

Proper shipping name : Environmentally hazardous substance, liquid, n.o.s. (Ivermectin)

Class : 9

Packing group : III

Labels : CLASS 9

ERG Code : 171

Marine pollutant : yes(Ivermectin)

Remarks : Above applies only to containers over 119 gallons or 450 liters., Shipment by ground under DOT is non-regulated; however it may be shipped per the applicable hazard classification to facilitate multi-modal transport involving ICAO (IATA) or IMO.

**Special precautions for user**

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

**SECTION 15. REGULATORY INFORMATION****CERCLA Reportable Quantity**

This material does not contain any components with a CERCLA RQ.

**SARA 304 Extremely Hazardous Substances Reportable Quantity**

This material does not contain any components with a section 304 EHS RQ.



## Ivermectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03/26/2022
8.2	04/09/2022	1204379-00015	Date of first issue: 01/09/2017

---

### SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.

**SARA 311/312 Hazards** : Reproductive toxicity  
 Specific target organ toxicity (single or repeated exposure)  
 Skin corrosion or irritation  
 Serious eye damage or eye irritation

**SARA 313** : The following components are subject to reporting levels established by SARA Title III, Section 313:

N-Methyl-2-pyrrolidone	872-50-4	10 %
------------------------	----------	------

### US State Regulations

#### Pennsylvania Right To Know

Fats and Glyceridic oils, sesame	8008-74-0
Ethyl oleate	111-62-6
N-Methyl-2-pyrrolidone	872-50-4

#### California Prop. 65

WARNING: This product can expose you to chemicals including N-Methyl-2-pyrrolidone, which is/are known to the State of California to cause birth defects or other reproductive harm. For more information go to [www.P65Warnings.ca.gov](http://www.P65Warnings.ca.gov).

#### California Permissible Exposure Limits for Chemical Contaminants

N-Methyl-2-pyrrolidone	872-50-4
------------------------	----------

#### The ingredients of this product are reported in the following inventories:

AICS	: not determined
DSL	: not determined
IECSC	: not determined


---

## SECTION 16. OTHER INFORMATION

### Further information

## Ivermectin Liquid Formulation

Version 8.2      Revision Date: 04/09/2022      SDS Number: 1204379-00015      Date of last issue: 03/26/2022  
 Date of first issue: 01/09/2017

**NFPA 704:****HMIS® IV:**

<b>HEALTH</b>	*	<b>4</b>
<b>FLAMMABILITY</b>		<b>1</b>
<b>PHYSICAL HAZARD</b>		<b>0</b>

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "\*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

**Full text of other abbreviations**

ACGIH BEI : ACGIH - Biological Exposure Indices (BEI)  
 US WEEL : USA. Workplace Environmental Exposure Levels (WEEL)  
 US WEEL / TWA : 8-hr TWA  
 US WEEL / STEL : Short-Term TWA

AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amend-

## Ivermectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03/26/2022
8.2	04/09/2022	1204379-00015	Date of first issue: 01/09/2017

---

ments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Revision Date : 04/09/2022

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

US / Z8